Startseite>>Signaling Pathways>> Others>> Adenylate cyclase>>TDI-10229

TDI-10229

Katalog-Nr.GC63213

TDI-10229 ist ein potenter und oral bioverfÜgbarer Inhibitor der lÖslichen Adenylylcyclase (sAC, ADCY10).

Products are for research use only. Not for human use. We do not sell to patients.

TDI-10229 Chemische Struktur

Cas No.: 2810887-45-5

Größe Preis Lagerbestand Menge
5 mg
270,00 $
Auf Lager
10 mg
432,00 $
Auf Lager
25 mg
855,00 $
Auf Lager
50 mg
855,00 $
Auf Lager
100 mg
2.025,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

TDI-10229 is a potent and orally bioavailable inhibitor of soluble adenylyl cyclase (sAC, ADCY10). TDI-10229 displays nanomolar inhibition of sAC in both biochemical and cellular assays (IC50 of 195 nM) and exhibits mouse pharmacokinetic properties sufficient to warrant its use as an in vivo tool compound[1][2].

TDI-10229 exhibits good permeability with an IC50 of 92 nM for human 4-4 cells[2].

TDI-10229 (5 mg/kg; p.o.) treatment shows the Cmax, AUC and MRT were 15.5 μM, 94 μg h/mL and 3.95 hours, respectively.

[1]. Balbach M, et al. Soluble adenylyl cyclase inhibition prevents human sperm functions essential for fertilization [published online ahead of print, 2021 Aug 31]. Mol Hum Reprod. 2021;gaab054.
[2]. Fushimi M, et al. Discovery of TDI-10229: A Potent and Orally Bioavailable Inhibitor of Soluble Adenylyl Cyclase (sAC, ADCY10). ACS Med Chem Lett. 2021;12(8):1283-1287. Published 2021 Jul 14.

Bewertungen

Review for TDI-10229

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TDI-10229

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.